CytoSorbents (NASDAQ:CTSO) has announced preliminary Q4 and full-year 2024 financial results.The company estimates Q4 product revenue between $9.0 million-$9.2 million vs. consensus of $9.45M ...

PRINCETON, N.J., Jan. 13, 2025 (GLOBE NEWSWIRE) -- CytoSorbents Corporation (NASDAQ: CTSO), a leader in the treatment of life-threatening conditions in the intensive care unit and cardiac surgery ...

Equities research analysts at StockNews.com assumed coverage on shares of Cytosorbents (NASDAQ:CTSO – Get Free Report) in a report released on Wednesday. The brokerage set a “hold” rating on the ...

(RTTNews) - Critical care company CytoSorbents Corp. (CTSO) announced Friday preliminary fourth-quarter results, expecting 22 percent to 25 percent growth in product revenue, while product gross ...

D. Boral Capital says CytoSorbents (CTSO) reported a strong Q4, with product revenue growth estimated between 22% and 25% year-over-year. The company also demonstrated a significant gross margin ...

Cytosorbents had a negative net margin of 49.47% and a negative return on equity of 118.54%. The business had revenue of $9.39 million during the quarter, compared to analysts’ expectations of ...

Analysts' ratings for CytoSorbents CTSO over the last quarter vary from bullish to bearish, as provided by 7 analysts. The table below offers a condensed view of their recent ratings, showcasing ...

Offering Proceeds Satisfies Debt Covenant, Unlocking $5.0 Million in Restricted Cash Currently on the Balance Sheet PRINCETON, N.J., Jan. 13, 2025 (GLOBE NEWSWIRE) -- CytoSorbents Corporation ...

Proceeds from the closing of the subscription period satisfy a debt covenant which allows for $5.0 million of restricted cash on CytoSorbents’ balance sheet to now become unrestricted ...

Offering Proceeds Satisfies Debt Covenant, Unlocking $5.0 Million in Restricted Cash Currently on the Balance Sheet PRINCETON, N.J., Jan. 13, 2025 (GLOBE NEWSWIRE) -- CytoSorbents Corporation (NASDAQ: ...